Industry Deep-Dive: Medical Treatment (Drugs, Biologics, Rehabilitation) vs. Surgical Treatment (Arthroplasty, Arthroscopy, Fusion)
Global Leading Market Research Publisher QYResearch announces the release of its latest report “General Musculoskeletal Treatment – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global General Musculoskeletal Treatment market, including market size, share, demand, industry development status, and forecasts for the next few years.
Core User Pain Point & Solution Direction: Orthopedic surgeons, rheumatologists, primary care physicians, and patients face a critical healthcare burden: musculoskeletal (MSK) conditions (osteoarthritis, rheumatoid arthritis, back pain, fractures, sports injuries, osteoporosis) affect over 1.7 billion people globally and are the leading cause of disability. Treatment options range from non-pharmacological (physical therapy, exercise) and pharmacological (NSAIDs, analgesics, corticosteroids, disease-modifying antirheumatic drugs (DMARDs), biologics) to surgical interventions (arthroplasty, arthroscopy, fracture fixation, spinal fusion, soft tissue repair). General musculoskeletal treatment encompasses both medical treatment (drugs, biologics, rehabilitation) and surgical treatment (procedures). The market is driven by aging populations (global population >65 years expected to double by 2050), increasing obesity (joint stress, osteoarthritis), sports-related injuries, and advances in biologic therapies (TNF inhibitors, IL-6 inhibitors, JAK inhibitors for inflammatory arthritis) and minimally invasive surgical techniques.
Global Market Size & Growth Trajectory
The global market for General Musculoskeletal Treatment was estimated to be worth US185,000millionin2025andisprojectedtoreachUS185,000millionin2025andisprojectedtoreachUS 275,000 million, growing at a CAGR of 5.8% from 2026 to 2032. Market growth is driven by global aging, increasing osteoarthritis prevalence (estimated 600 million affected globally), rising demand for joint replacement (knee, hip, shoulder), biosimilar entry reducing biologic costs (expanding access), and minimally invasive surgical techniques (shorter recovery).
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5983903/general-musculoskeletal-treatment
Market Share & Competitive Landscape
The market features a consolidated landscape with large pharmaceutical companies, biologic manufacturers, and orthopedic device companies:
- Pfizer – Global leader (pharmaceutical and anti-inflammatory portfolio), approximately 8% market share.
- Amgen – Approximately 6% share (biologics for osteoporosis, inflammatory arthritis: Prolia, Enbrel).
- Eli Lilly – Approximately 5% share (arthritis, pain, osteoporosis: Cymbalta, Forteo, Taltz).
- Sanofi, Boehringer Ingelheim, Merck, AstraZeneca – Pharmaceutical and biologic players.
- Horizon Therapeutics – Rare disease and rheumatology (Krystexxa, UPLIZNA).
- Teva, Sun Pharma – Generic analgesics and anti-inflammatories.
- Biogen, Eisai, Sino Biopharmaceutical – Select musculoskeletal portfolios.
- Procter & Gamble – OTC analgesics (NSAIDs).
The top three (Pfizer, Amgen, Eli Lilly) account for approximately 19% of global market share, reflecting a highly fragmented market across numerous therapeutic categories.
Type Segmentation
- Medical Treatment (72% share) – Largest segment, 5.5% CAGR. Includes: (a) NSAIDs (ibuprofen, naproxen, celecoxib), (b) analgesics (acetaminophen, opioids for severe pain), (c) corticosteroids (oral, intra-articular injections), (d) DMARDs (methotrexate, sulfasalazine, hydroxychloroquine), (e) biologic DMARDs (TNF inhibitors, IL-17, IL-23, JAK inhibitors), (f) osteoporosis drugs (bisphosphonates, denosumab, teriparatide), (g) hyaluronic acid injections (viscosupplementation for knee OA), (h) platelet-rich plasma (PRP) and stem cell therapies (regenerative medicine).
- Surgical Treatment (28% share) – Fastest-growing segment (6.2% CAGR). Includes: (a) total joint arthroplasty (knee, hip, shoulder, ankle), (b) arthroscopy (meniscectomy, ACL reconstruction, rotator cuff repair), (c) fracture fixation (plates, screws, intramedullary nails, external fixators), (d) spinal surgery (discectomy, laminectomy, fusion), (e) soft tissue repair (ligament, tendon).
Application Segmentation
- Hospital (70% share) – Largest segment, 5.6% CAGR. Inpatient surgical procedures, infusion therapies (biologics, osteoporosis drugs), inpatient rehabilitation.
- Ambulatory Surgery Center (20% share) – Fastest-growing segment (8.0% CAGR). Outpatient arthroscopy, joint replacement (rapid recovery protocols, 23-hour stays), pain management injections.
- Others (10% share) – Physician offices (office-based injections, medication management), urgent care centers, physical therapy clinics.
Clinical Deep-Dive: Major MSK Condition Treatment Pathways
| Condition | Medical Treatment | Surgical Treatment | Market Drivers |
|---|---|---|---|
| Osteoarthritis (knee, hip) | NSAIDs, analgesics, hyaluronic acid, corticosteroid injections | Total knee arthroplasty (TKA), total hip arthroplasty (THA) | Aging, obesity (40-50% lifetime risk of knee OA) |
| Rheumatoid Arthritis | Methotrexate (first-line), biologic DMARDs (TNFi, IL-6i, JAKi) | Synovectomy (rare), joint replacement (end-stage) | Autoimmune prevalence (0.5-1% global) |
| Osteoporosis | Bisphosphonates (alendronate), denosumab (Prolia), teriparatide (Forteo) | Vertebroplasty, kyphoplasty (fracture stabilization) | Aging (50% women >50 have low bone mass) |
| Back Pain | NSAIDs, muscle relaxants, opioids (short-term), epidural steroid injections | Discectomy, laminectomy, spinal fusion | Leading cause of disability globally |
| Fractures | Analgesics, immobilization (casting) | ORIF (plates, screws), IM nailing, external fixation | Trauma, osteoporosis (1/3 adults >65 fall annually) |
Recent Technical Breakthrough (Q1 2025) – A persistent challenge in medical treatment for osteoporosis has been poor adherence to oral bisphosphonates (weekly dosing complexity, GI side effects). Amgen’s Prolia (denosumab, twice-yearly subcutaneous injection) now has 10-year safety and efficacy data (extension study) showing continued fracture risk reduction (68% vertebral, 40% non-vertebral) with stable adherence (85-90% vs. 30-40% for oral bisphosphonates). Generic denosumab expected 2026-2028 (US market), expanding access.
Typical User Case (Q2 2025) – A 72-year-old female with severe osteoarthritis (left knee, K-L grade IV, 10 years duration, BMI 31) failed conservative treatment (NSAIDs, physical therapy, 3 series of hyaluronic acid injections over 5 years, symptom relief 4-6 months each). Underwent total knee arthroplasty (TKA, outpatient rapid recovery protocol). Results: Pain reduced from 8/10 to 2/10 (VAS), functional improvement (walking without assistive device), LOS 23 hours (discharged home, home physical therapy). Implant survival 15-20 years expected. Total cost (hospital, surgeon, implant, anesthesia, PT): US35,000coveredbyMedicare(patientout−of−pocketUS35,000coveredbyMedicare(patientout−of−pocketUS 1,500).
Exclusive Observation: The Biologic Shift in Inflammatory Arthritis
The treatment paradigm for rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS) has shifted dramatically from traditional DMARDs (methotrexate) to biologic DMARDs and targeted synthetic DMARDs (JAK inhibitors):
| Era | Dominant Treatment | Efficacy (ACR50) | Market Share (by revenue) |
|---|---|---|---|
| Pre-2000 | Methotrexate, corticosteroids | 30-40% | N/A (generic, low cost) |
| 2000-2015 | TNF inhibitors (Enbrel, Humira, Remicade) | 50-60% | 60-70% of biologic market |
| 2015-2025 | New biologics (IL-6, IL-17, IL-23) + JAK inhibitors (Xeljanz, Rinvoq, Olumiant) | 60-70% | 30-40% (biosimilar erosion of TNFi) |
| 2025-2032 | Biosimilars (Humira biosimilars, Enbrel biosimilars) + oral JAK inhibitors | 60-65% | Prices declining, volume increasing |
Impact on market growth: Biologics (US10,000−50,000perpatient−year)drovemarketgrowthfrom2010−2020.Biosimilarentry(2023−2025)reducespricesby50−8010,000−50,000perpatient−year)drovemarketgrowthfrom2010−2020.Biosimilarentry(2023−2025)reducespricesby50−80 30,000-40,000/year) offer convenience but carry boxed warnings (cardiovascular, thrombosis). Market value growth slows, but volume continues increasing (untreated inflammatory arthritis patients, especially in emerging markets).
Industry Segmentation: Pharmaceutical vs. Device vs. Biologic Manufacturing
General musculoskeletal treatment spans three distinct industry segments:
| Segment | Market Share (2025) | Key Players | Gross Margin | Barriers |
|---|---|---|---|---|
| Pharmaceuticals (NSAIDs, analgesics, corticosteroids, DMARDs, opioids) | 40% | Pfizer, Teva, J&J, Bayer | 40-70% (branded), 15-30% (generic) | Regulatory, generic competition |
| Biologics (TNF inhibitors, IL inhibitors, JAK inhibitors, osteoporosis biologics) | 35% | Amgen, AbbVie, Eli Lilly, Roche | 70-85% (innovator), 40-60% (biosimilar) | Manufacturing complexity, clinical development |
| Surgical/Orthopedic Devices (implants, instruments, arthroscopy) | 25% | Stryker, DePuy Synthes (J&J), Zimmer Biomet | 60-75% | FDA 510(k), surgeon training, installed base |
Cost structure (biologic DMARD, innovator, annual patient cost US$ 30,000-50,000):
| Component | Percentage |
|---|---|
| R&D amortization (including failed programs) | 20-30% |
| Manufacturing (cell culture, purification, fill/finish) | 10-20% |
| Clinical trials (ongoing post-marketing) | 5-10% |
| Sales and marketing (detailing to rheumatologists) | 20-30% |
| Patient assistance (co-pay cards, free drug programs) | 5-15% |
| Margin (innovator) | 20-30% |
Additional Market Dynamics: The musculoskeletal treatment market faces challenges from (1) opioid epidemic (restricting opioid use for chronic MSK pain), (2) biosimilar/generic price erosion (reducing revenue for innovator products), (3) surgical procedure shift to outpatient (lower facility fees, reduced hospital revenue), (4) non-pharmacological alternatives (physical therapy, acupuncture, exercise) gaining coverage, (5) delay of elective procedures during respiratory virus seasons (staffing constraints). However, the combination of aging populations, obesity epidemic (joint stress), and advances in biologic therapies (targeted, more effective) and minimally invasive surgery (faster recovery) positions the general musculoskeletal treatment market for sustained 5-7% annual growth through 2032.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
